Navigation Links
Larynx preservation preferred over total laryngectomy
Date:2/1/2008

Patients with locally advanced laryngopharyngeal cancers who receive radical chemoradiation have significantly better voice outcomes during the 12 months following treatment when compared with patients who have undergone a total laryngectomy and surgical voice restoration, according to a study in the February 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

The conventional treatment for patients with advanced squamous carcinoma of the larynx has traditionally been a total laryngectomy, which is the removal of the voice box, with or without radiation; however, this treatment has several serious side effects, including natural-voice loss, altered food-swallowing function and a permanent opening in the trachea.

Researchers in this study, conducted jointly by the Royal Marsden Hospital Head and Neck Unit and The Institute of Cancer Research, both in London, sought to determine if larynx preservation through chemoradiation would result in improved voice results and serve as a suitable alternative to total laryngectomy, which, in turn, would remove the need for surgery and all of the related potential side effects and risks.

Twenty-one patients, both male and female, with a median age of 65 years old, who were diagnosed with Stage III or IV laryngopharyngeal cancer, were given induction chemotherapy followed by radical chemoradiation. The researchers then used electroglottography placing electrodes alongside the larynx to electronically record and analyze the voice function of the patients before treatment and at one, six and 12 months after treatment. This is the first study of its kind to use electroglottography as an assessment technique.

Patients were asked to read a standard passage and pronounce vowel sounds into a microphone that sat at the same distance from the mouth of each patient. The researchers then used these recordings to measure jitter in the voice, maximum phonation time and words per minute.

Single voice recordings were also taken from 21 patients, with a median age of 65 years old, who received a total laryngectomy and surgical voice restoration, as well as from 21 normal controls of the same median age group.

The researchers found that preservation of the larynx through chemoradiation did not always return voice quality to exactly how it was before the tumor was present, but it did provide for significantly better voice outcomes when compared to removing the larynx through surgery. At 12 months after treatment, the patients receiving chemoradiation had normal maximum phonation time and words per minute, but less than normal jitter.

This study is important because it offers patients reassurance that if they undergo organ preservation, it is statistically proven that their voice will be better than if they undergo surgery. We can reassure patients that their voice is likely to recover from the immediate effects of chemoradiation, said Kevin Harrington, M.B.B.S., clinical senior lecturer at The Institute of Cancer Research. This study should also allay the concerns of surgeons that laryngopharyngeal cancer patients cannot be successfully treated with chemoradiation with good functional outcome.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Therapeutic Radiology and Oncology
Source:Eurekalert

Related medicine news :

1. New research suggests hearts are experts at self-preservation
2. The aye-ayes have it: The preservation of color vision in a creature of the night
3. Mylan Declares Quarterly Preferred Stock Dividend
4. NHP Increases Its Quarterly Common Dividend by $0.03 and Declares Its Quarterly Cash Dividends on Common Stock and Series B Preferred Stock
5. Wyeth Declares Common and Preferred Stock Dividends
6. Smart Balance Announces Conversion of Convertible Preferred Stock
7. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo
10. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of ... opportunity for area-residents to celebrate two great years while also familiarizing themselves with ...
(Date:3/27/2017)... HOUSTON, Texas (PRWEB) , ... March 27, 2017 , ... ... and hard of hearing, is bringing its latest products to the Deaf Seniors of ... attendees will have the opportunity to meet with knowledgeable ASL friendly staff from Harris ...
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
(Date:3/24/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) has named ... in their 12th year, are among the most prestigious in radiology marketing because a ... were retooled to recognize achievements in both large budget (over $5,000) and small budget ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... and technology platform for value-based precision medicine, ... multi-year collaboration with Novartis Pharmaceuticals Corporation to ... breast cancer patients. As part ... the previous announced collaboration entered into January ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology: